Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegis Therapeutics, a provider of drug delivery and drug formulation technologies, has received US patent for its GLP-1 peptide analogs.
Subscribe to our email newsletter
GLP-1 peptide analogs are suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes or injection.
Aegis’ patented drug delivery and drug formulation technologies include Intravail drug delivery technology which enables the non-invasive delivery of a protein, peptide and non-peptide drugs.
The ProTek technology is used for aqueous or lyophilized dosage forms to maintain product integrity and reduce unwanted immunogenicity of protein and peptide therapeutics.